Vascularization is a key challenge in the regeneration of tissues containing blood vessels. In this study, spermine was used for cationic modification of Antheraea pernyi silk fibroin (ASF) to synthesize cationized ASF (CASF). CASF/Ad complexes prepared by coating adenovirus (Ad) with CASF were used as delivery vectors for vascular endothelial growth factor 165 and angiopoietin-1 dual genes. The results showed that the zeta potential of the Ad was reversed from −7.75 mV to approximately +8.40 mV after CASF coating, and the sizes of the CASF/Ad complexes were 200 to 290 nm. Furthermore, human umbilical vein endothelial cells HUVECs were cocultured and infected with CASF/Ad in vitro. The results of confocal laser scanning microscopy, flow cytometry and CCK-8 assay showed that coating Ad with CASF at concentration of 20 and 50 µg/mL not only reduced the cytotoxicity of naked Ad, but also significantly promoted cell proliferation. Therefore, the CASF/Ad complexes could be beneficial to reduce the dosage of Ad and the potential toxicity risk of high doses of Ad in vivo, which has the potential of application to promote vascular network regeneration.
ToccoIZavanBBassettoF, et al. Nanotechnology-based therapies for skin wound regeneration. J Nanomat2012; 2012(4): 1–11.
2.
HanXSunMChenB, et al. Lotus seedpod-inspired internal vascularized 3D printed scaffold for bone tissue repair. Bioact Mater2021; 6(6): 1639–1652.
3.
JohnsonKEWilgusTA.Vascular endothelial growth factor and angiogenesis in the regulation of cutaneous wound repair. Adv Wound Care2014; 3(10): 647–661.
4.
GrigoryanBPaulsenSJCorbettDC, et al. Multivascular networks and functional intravascular topologies within biocompatible hydrogels. Science2019; 364(6439): 458–464.
5.
WangBHuangYHuangZ, et al. Self-assembling in situ gel based on lyotropic liquid crystals containing VEGF for tissue regeneration. Acta Biomater2019; 99(2): 84–99.
6.
MinSClevelandDKoIK, et al. Accelerating neovascularization and kidney tissue formation with a 3D vascular scaffold capturing native vascular structure. Acta Biomater2021; 124(7): 233–243.
7.
WangZJinCLiX, et al. Sulfated polysaccharide JCS1S2 inhibits angiogenesis via targeting VEGFR2/VEGF and blocking VEGFR2/Erk/VEGF signaling. Carbohydr Polym2019; 207(1): 502–509.
DasALauffenburgerDAsadaH, et al. Determining cell fate transition probabilities to VEGF/Ang 1 levels: relating computational modeling to microfluidic angiogenesis studies. Cell Mol Bioeng2010; 3(4): 345–360.
10.
KandaSMiyataYMochizukiY, et al. Angiopoietin 1 is mitogenic for cultured endothelial cells. Cancer Res2005; 65(15): 6820–6827.
11.
PapapetropoulosAFultonDMahboubiK, et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway. J Biol Chem2000; 275(13): 9102–9105.
12.
ChiuLLYRadisicM. Scaffolds with covalently immobilized VEGF and angiopoietin-1 for vascularization of engineered tissues. Biomatter2010; 31(2): 226–241.
MatsumineHFujimakiHTakagiM, et al. Full-thickness skin reconstruction with basic fibroblast growth factor-impregnated collagen-gelatin sponge. Regen Therapy2019; 11:81–87.
15.
LeonardAKoriaP.Growth factor functionalized biomaterial for drug delivery and tissue regeneration. J Bioact Compat Polym2017; 32(6): 568–581.
16.
HittiFLYangAIGonzalez-AlegreP, et al. Human gene therapy approaches for the treatment of Parkinson’s disease: an overview of current and completed clinical trials. Parkinsonism Relat Disord2019; 66:16–24.
17.
JazwaAJozkowiczADulakJ.New vectors and strategies for cardiovascular gene therapy. CurrGene Ther2007; 7(1): 7–23.
18.
ThomasCEEhrhardtAKayMA.Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet2003; 4(5): 346–358.
19.
YinHKanastyRLEltoukhyAA, et al. Non-viral vectors for gene-based therapy. Nat Rev Genet2014; 15(8): 541–555.
20.
ZhouZLiuXZhuD, et al. Nonviral cancer gene therapy: delivery cascade and vector nanoproperty integration. Adv Drug Deliv Rev2017; 115:115–154.
21.
DiazILJérômeVFreitagR, et al. Development of poly(ethyleneimine) grafted amphiphilic copolymers: evaluation of their cytotoxicity and ability to complex DNA. J Bioact Compat Polym2021; 36(6): 447–463.
22.
LeeCSBishopESZhangR, et al. Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Dis2017; 4(2): 43–63.
23.
GoswamiRSubramanianGSilayevaL, et al. Gene therapy leaves a vicious cycle. Front Oncol2019; 9:297–322.
24.
LuoHChenYYeZ, et al. Evaluation of the association between common genetic variants near the ABCA1Gene and primary angle closure glaucoma in a Han Chinese population. Investig Ophthalmol Vis Sci2015; 56(11): 6248–6254.
25.
KnowlesMRHohnekerKWZhouZ, et al. A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis. New Engl J Med1995; 333(13): 823–831.
26.
GuptaSDuttaPAcharyaV, et al. Accelerating skin barrier repair using novel bioactive magnesium-doped nanofibers of non-mulberry silk fibroin during wound healing. J Bioact Compat Polym2022; 37(1): 38–52.
27.
ChengXLongDChenL, et al. Electrophoretic deposition of silk fibroin coatings with pre-defined architecture to facilitate precise control over drug delivery. Bioact Mater2021; 6(11): 4243–4254.
28.
ChengXDengDChenL, et al. Electrodeposited assembly of additive-free silk fibroin coating from pre-assembled nanospheres for drug delivery. ACS Appl Mater Interfaces2020; 12(10): 12018–12029.
29.
SezutsuHYukuhiroK.Dynamic rearrangement within the Antheraea pernyi silk fibroin gene is associated with four types of repetitive units. J Mol Evol2000; 51(4): 329–338.
30.
MoriHTsukadaM.New silk protein: modification of silk protein by gene engineering for production of biomaterials. J Biotechnol2000; 74(2): 95–103.
KadakiaPUGrowney KalafEADunnAJ, et al. Comparison of silk fibroin electrospun scaffolds with poloxamer and honey additives for burn wound applications. J Bioact Compat Polym2018; 33(1): 79–94.
33.
CerroniBRivaFROddoL, et al. In vitro analysis of the trajectories of adhesive microbubbles approaching endothelial cells. J Colloid Interface Sci2020; 578:758–767.
34.
MaCLvLLiuY, et al. Antheraea pernyi silk fibroin for targeted gene delivery of VEGF165-Ang-1 with PEI. Biomed Mater2014; 9(3): 035015.
35.
LiXZhangJFengY, et al. Tuning the structure and performance of silk biomaterials by combining mulberry and non-mulberry silk fibroin. Polym Degrad Stab2018; 147:57–763.
36.
QuJWangWFengY, et al. Int J Nanomedicine2019; 14(1): 9745–9761.
37.
ZhaoMQiZTaoX, et al. Chemical, thermal, time, and enzymatic stability of silk materials with silk I structure. Int J Mol Sci2021; 22(8): 4136–4152.
38.
WangDTaiPWLGaoG.Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov2019; 18(5): 358–378.
39.
ZhuFCLiYHGuanXH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet2020; 395(10240): 1845–1854.
40.
LiMYuYHuY, et al. Spermine-modified Antheraea pernyi silk fibroin as a gene delivery carrier. Int J Nanomedicine2016; 11:1013–1023.
41.
RappoportJZ.Focusing on clathrin-mediated endocytosis. Biochem J2008; 412(3): 415–423.
42.
RejmanJOberleVZuhornIS, et al. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem J2004; 377(1): 159–169.
43.
TakahashiHNiidomeTKawanoT, et al. Surface modification of gold nanorods using layer-by-layer technique for cellular uptake. J Nanopart Res2008; 10(1): 221–228.
44.
Redd BowmanKELuPVander MauseER, et al. Advances in delivery vectors for gene therapy in liver cancer. Ther Deliv2020; 11(1): 833–850.
45.
LuoZLiJQuJ, et al. Cationized Bombyx mori silk fibroin as a delivery carrier of the VEGF165-Ang-1 coexpression plasmid for dermal tissue regeneration. J Mater Chem B2019; 7(1): 80–94.
46.
LeeYLeeJKimM, et al. Brain gene delivery using histidine and arginine-modified dendrimers for ischemic stroke therapy. J Control Release2021; 330:907–919.
